KLRS (Kalaris Therapeutics) Treasury Stock: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRS Kalaris Therapeutics Inc KLRS
12 GF Score
Price $3.97
View Full Analysis

What is Kalaris Therapeutics Treasury Stock?

Kalaris Therapeutics KLRS +0.76% 12 Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus rates KLRS with a GF Score™ of 12/100.

Treasury stock is the portion of shares that a company keeps in their own treasury. Kalaris Therapeutics's treasury stock for the quarter that ended in Mar. 2026 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Kalaris Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Kalaris Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kalaris Therapeutics Treasury Stock Chart

Kalaris Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Treasury Stock
0.00 0.00 0.00 0.00

Kalaris Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
KLRS
12GF Score
Kalaris Therapeutics Inc KLRS
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kalaris Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $0.00 Mil mean?
Kalaris Therapeutics (KLRS) has a Treasury Stock of $0.00 Mil as of Mar. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Kalaris Therapeutics and its competitors.
Is Kalaris Therapeutics' Treasury Stock too high?
Kalaris Therapeutics' current Treasury Stock is $0.00 Mil. Overall, Kalaris Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kalaris Therapeutics' Treasury Stock compare to HRTX and VRCA?
Kalaris Therapeutics' Treasury Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Kalaris Therapeutics and its competitors. Kalaris Therapeutics's current Treasury Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kalaris Therapeutics stock overvalued right now?
Kalaris Therapeutics (KLRS) has a current Treasury Stock of $0.00 Mil. The current Treasury Stock is $0.00 Mil. Kalaris Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Kalaris Therapeutics (KLRS), the current Treasury Stock is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kalaris Therapeutics Business Description

Address 400 Connell Drive, Suite 5500, Berkeley Heights, NJ, USA, 07922
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
12GF Score

Get the complete analysis for KLRS

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.97
Price